International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.

[1]  P. Kaleebu,et al.  Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of Adenoviridae , 2010, Journal of Virology.

[2]  J. Baeten,et al.  Frequent Detection of Human Adenovirus from the Lower Gastrointestinal Tract in Men Who Have Sex with Men , 2010, PloS one.

[3]  N. Wolfe,et al.  International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. , 2010, Vaccine.

[4]  Devan V Mehrotra,et al.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.

[5]  Donald K Carter,et al.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis , 2008, The Lancet.

[6]  D. Montefiori,et al.  Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys , 2008, Nature.

[7]  J. Kublin,et al.  Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  K. Mansfield,et al.  Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys , 2008, Journal of Virology.

[9]  C. Napoli,et al.  Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer , 2008, Cell.

[10]  R. Koup,et al.  Myeloid and Plasmacytoid Dendritic Cells Are Susceptible to Recombinant Adenovirus Vectors and Stimulate Polyfunctional Memory T Cell Responses , 2007, The Journal of Immunology.

[11]  K. Mansfield,et al.  Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D , 2007, Journal of Virology.

[12]  J. Mascola,et al.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. , 2006, The Journal of infectious diseases.

[13]  Punnee Pitisuttithum,et al.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.

[14]  P. Jeena,et al.  Age Dependence of Adenovirus-Specific Neutralizing Antibody Titers in Individuals from Sub-Saharan Africa , 2006, Journal of Clinical Microbiology.

[15]  K. Mansfield,et al.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity , 2006, Nature.

[16]  Kenneth H Mayer,et al.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.

[17]  B. Berkhout,et al.  Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector , 2004, AIDS.

[18]  S. Kostense,et al.  Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity1 , 2004, The Journal of Immunology.

[19]  Jaap Goudsmit,et al.  Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors , 2003, Journal of Clinical Microbiology.

[20]  S. Kostense,et al.  Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity , 2003, Journal of Virology.

[21]  R. K. Evans,et al.  Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene , 2003, Journal of Virology.

[22]  Z. Xiang,et al.  A Simian Replication-Defective Adenoviral Recombinant Vaccine to HIV-1 Gag 1 , 2003, The Journal of Immunology.

[23]  R. M. Burnett,et al.  Replication-Defective Vector Based on a Chimpanzee Adenovirus , 2001, Journal of Virology.